Literature DB >> 25872165

Development and validation of a new assay for assessing clot integrity.

P Ranjit1, Y Lau1, G Y H Lip1, A D Blann2.   

Abstract

INTRODUCTION: Research and routine laboratory assessment of clot integrity can be time consuming, expensive, and cannot be batched as it is generally performed in real time. To address these issues, we developed and validated a micro-titre based assay to quantify thrombogenesis and fibrinolysis, the purpose being to assess patients at risk of cardiovascular events by virtue of hypercoagulability. In further validation, thrombogenesis results were compared to similar indices from the thrombelastograph (TEG).
METHODS: Our assay determines three indices of thrombogenesis (lag time to the start of thrombus formation (LT), rate of clot formation (RCF), and maximum clot density (MCD)) and two of fibrinolysis (rate of clot dissolution (RCD) and time for 50% of the clot to lyse (T50)). Plasma was tested fresh and again after being frozen at -70°C. Some samples were tested immediately, others after being left at room temperature for up to 24h.
RESULTS: The intra-assay coefficients of variation (CVs) of the three thrombogenesis measures (LT, RCF, MCD) and two fibrinolysis measures (RCD, T50) varied between 2.7 and 12.0% in fresh plasma and between 1.3% and 10.8% in frozen plasma respectively. Similarly, the inter-assay coefficients of variation of the thrombogenesis and fibrinolysis measures were 4.9-10.8% in fresh plasma and 2.2-6.5% in frozen plasma respectively. TEG assays intra- and inter assay CVs were around 25%. There were no significant differences in all plate assay indices up to 6h at room temperature. Certain plate assay thrombogenesis data were comparable to TEG indices after analysis by Pearson's correlation. The reagent processing cost per sample is £15 for TEG and £2 for the plate assays.
CONCLUSION: Our micro-titre based assay assessing plasma thrombogenesis and fibrinolysis has good intra- and inter-assay CVs, can assess plasma up to 6h after venepuncture, is more efficient (in terms of throughput) and is more economical than that of the TEG.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fibrinolysis; Haemostasis; Kaolin; Thrombelastograph; Thrombin; Thrombosis; Tissue plasminogen activator

Mesh:

Year:  2015        PMID: 25872165     DOI: 10.1016/j.vph.2015.02.013

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  3 in total

1.  Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation.

Authors:  Yee Cheng Lau; Qinmei Xiong; Eduard Shantsila; Gregory Y H Lip; Andrew D Blann
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

2.  Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis.

Authors:  Y C Lau; Q Xiong; P Ranjit; G Y H Lip; A D Blann
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

3.  Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y12 Receptor Antagonists.

Authors:  Nina Wolska; Magdalena Boncler; Dawid Polak; Joanna Wzorek; Tomasz Przygodzki; Magdalena Gapinska; Cezary Watala; Marcin Rozalski
Journal:  Molecules       Date:  2019-12-28       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.